Evidence map›Paper›PMID 33791200›Full record

ArticleFrontiers in oncology2021

Using Endoscopic Optical Coherence Tomography to Detect and Treat Early-Stage Pancreatic Cancers.

Lanchun Lu, Zhilin Hu, Wendy Frankel, Rulong Shen, Wei Chen, Xueliang Pan, John C Grecula, Mark P Bloomston, Mary E Dillhoff

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Lanchun LuDepartment of Radiation Oncology, The James Cancer Hospital and Solove Research Institute, Wexner Medical Center and College of Medicine at the Ohio State University, Columbus, OH, United States.
Zhilin HuPharos Scientific, LLC, Lilburn, GA, United States.
Wendy FrankelDepartment of Pathology, The James Cancer Hospital and Solove Research Institute, Wexner Medical Center and College of Medicine at the Ohio State University, Columbus, OH, United States.
Rulong ShenDepartment of Pathology, The James Cancer Hospital and Solove Research Institute, Wexner Medical Center and College of Medicine at the Ohio State University, Columbus, OH, United States.
Wei ChenDepartment of Pathology, The James Cancer Hospital and Solove Research Institute, Wexner Medical Center and College of Medicine at the Ohio State University, Columbus, OH, United States.
Xueliang PanDepartment of Biomedical Informatics, College of Medicine at the Ohio State University, Columbus, OH, United States.
John C GreculaDepartment of Radiation Oncology, The James Cancer Hospital and Solove Research Institute, Wexner Medical Center and College of Medicine at the Ohio State University, Columbus, OH, United States.
Mark P Bloomston21st Century Oncology, Fort Myers, FL, United States.
Mary E DillhoffDepartment of Surgical Oncology, The James Cancer Hospital and Solove Research Institute, Wexner Medical Center and College of Medicine at the Ohio State University, Columbus, OH, United States.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · US21st Century Oncology (United States) · USThe Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We developed a novel technology capable of detecting early-stage pancreatic cancers using high-resolution three-dimensional endoscopic optical coherence tomography (Endo-OCT), and treating them using high dose rate brachytherapy (HDR) under the Endo-OCT image guidance. This technology integrates our custom-built ultra-high resolution endoscopic three-dimensional OCT diagnostic imaging device with a commercial high dose rate brachytherapy system (HDR), resulting in a compact, portable, easy-to-operate, and low-cost Endo-OCT image-guided high dose rate brachytherapy (OCT-IGHDR) system. The system has the dual functions of diagnosis and treatment that can precisely detect and measure the location and size of the early-stage pancreatic cancer or premalignant lesions and then treat them from the inside of the pancreatic duct with an accurate and focused dose while greatly reducing the radiation toxicity to the neighboring tissues and organs. This minimally-invasive treatment technology could avoid the potential complications from surgery and reduces the high operation cost. This technology could also be applied to treat diseases of the esophagus, rectum, bronchus, and other aerodigestive organs that are suitable for use with an endoscopic device. In this article, we describe the concept of this technology and the preliminary experiments that could demonstrate the concept by using this homemade Endo-OCT machine to image the pancreatic duct for diagnosis of early-stage pancreatic cancer or premalignant lesions and to perform Endo-OCT image-guided brachytherapy.

Indexed as

detect and treatearly-stage pancreatic cancerendo-optical coherence tomography–guided brachytherapyendoscopic optical coherence tomographyhigh-dose rate brachytherapy

Identifiers

PMID33791200
PMCPMC8005647
OpenAlexW3136314749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.